BRAIN 2022 Goes Virtual

In response to the rapidly changing COIVI-19 outbreak in Hong Kong, the BRAIN 2022 Conference will be held FULLY VIRTUAL.

WELCOME MESSAGE

BRAIN 2022 - the 18th Multidisciplinary Meeting for Nervous System Diseases, is jointly organized by Division of Neurology, Neuropathology and Division of Neurosurgery, The Chinese University of Hong Kong (CUHK), we are committed to advance neurological science by promoting in-depth communication among all local and overseas neurologists, neurosurgeons, pathologists, clinical and preclinical scientists and related healthcare professionals.

We strive to bring all participants a great line-up of discussion on Parkinson’s Disease, Alzheimer’s Disease, Stroke, and Brain Tumours.

Go Virtual
Breaking geographic boundaries, the conference will be held fully virtual via online webinar.

Join us in this exciting event and share the passion on advancing knowledge and gaining new insights.



Organisers

Division of Neurology
Neuropathology
Division of Neurosurgery
The Chinese University of Hong Kong

Supporting Organisations

Hong Kong Neurological Society
Hong Kong Neuro-oncology Society
The Hong Kong Neurosurgical Society
The Hong Kong Neurosurgical Society (Nursing Chapter)
Hong Kong Student Association of Neuroscience
International Academy of Pathology, Hong Kong Division

FACULTY
(in alphabetical order)


 X
Xiaodong CAI
Professor of Neurosurgery
Director of Functional Neurosurgery
Department of Neurosurgery, The First Affiliated Hospital of Shenzhen University/ Shenzhen Second People's Hospital Shenzhen, China

Xiaodong obtained his medical degree (1988) and Master of Medicine (1997) respectively from Luzhou Medical College and West China School of Medicine/ West China Hospital, Sichuan University, China. He did his functional neurosurgery training (2002-2004) in Hidaka Hospital, Wakayama, Japan, a two-year mentorship of Professor Chihiro Ohye. Xiaodong joined the Frist Affiliated Hospital of Shenzhen University/ Shenzhen Second People’s Hospital (SZSPH) in 1997 and has become an academic neurosurgeon since 2006). He is currently Professor of Neurosurgery and Director of Functional Neurosurgery of SZSPH. He also serves as Director of Shenzhen Parkinson’s Disease and other Movement Disorders Center, Vice Chair of Shenzhen Association of Neurosurgeons, Director of Shenzhen Functional Brain Diseases Center of Shenzhen Sami Medical Center. Xiaodong’s clinical and research interests are DBS for movement disorders, epilepsy and microvascular decompression for trigeminal neuralgia, glossopharyngeal neuralgia and hemifacial spasm.

Xiaodong CAI
Department of Neurosurgery
The First Affiliated Hospital of Shenzhen University/ Shenzhen Second People's Hospital
 X
Danny Tat-Ming CHAN
Head & Clinical Associate Professor (Honorary)
Division of Neurosurgery
Department of Surgery
The Chinese University of Hong Kong, Hong Kong

Danny is a medical graduate at The Chinese University of Hong Kong (CUHK). He completed his specialist training in Neurosurgery in 2004 and was awarded the Douglas Miller Gold Medal for distinction in Neurosurgery by The College of Surgeons of Hong Kong and The Royal College of Surgeons, Edinburgh. He received his overseas training for Neuro-Oncology in MD Anderson Cancer Centre under the mentorship of Professor Alfred Wai-Kwan Yung in 2007.

Danny is currently Honorary Clinical Associate Professor and the Head of the Division of Neurosurgery at Department of Surgery, Prince of Wales Hospital (PWH) / CUHK, and Associate Director of the CUHK Otto Wong Brain Tumour Centre. His special interests include Neuro-Oncology, glioma surgery and functional Neurosurgery. In 2009. He and his team established the first one-stop multidisciplinary combined neuro-oncology clinic (CNO) for management of brain tumour patients in Hong Kong. They also introduced awake cortical mapping and fluorescence guided surgery for the management of gliomas. Danny is the founding organiser of the "Hong Kong - Walk around the World for Brain Tumours" Awareness Program (since 2007).

Danny Tat-Ming CHAN
Division of Neurosurgery, Department of Surgery
Prince of Wales Hospital/
The Chinese University of Hong Kong
 X
Kannie Wai-Yan CHAN
Associate Professor
Department of Biomedical Engineering
City University of Hong Kong, Hong Kong

Dr. Kannie Wai-Yan CHAN's research focuses on the development of biomaterials and imaging approaches to facilitate the clinical translation of cancer therapy and cell therapy, and early diagnosis of neurodegenerative diseases. She received her BSc and PhD degrees from The University of Hong Kong. She completed post-doctoral fellowships in magnetic resonance imaging (MRI) at Department of Radiology, Johns Hopkins University School of Medicine, and became an Assistant Professor in 2014. She joined City University of Hong Kong in 2016. She is a leading researcher in applying a frontier molecular MRI contrast mechanism to address clinical needs, which is known as chemical exchange saturation transfer (CEST). She has pioneered the imaging of glucose utilization in the brain using CEST-MRI. The way how our brain uses glucose could have implications on diagnosis and therapy in many neurological disorders, including Alzheimer's disease and stroke. Her team is developing various techniques to effectively image and deliver drugs/cells in the brain non-invasively. She published over 60 peer-reviewed articles, including a cover article in Nature Materials, Science Advances, Theranostics and Nature Communications. She is a corporate member of HKIE, an adjunct faculty of Johns Hopkins University School of Medicine, and an associate director of COCHE. She served as AMPC member of ISMRM and is now at the publication committee of ISMRM

Kannie Wai-Yan CHAN
Department of Biomedical Engineering
City University of Hong Kong

 X
Binith Joseph CHEERAN
Senior Director
Clinical and Medical Affairs
Neurological Disorder Therapies, Abbott Texas, USA

Binith is the Medical and Clinical Affairs Senior Director at Abbott Labs, a Clinical Neurologist and Ph.D. Neuroscientist. After training in Internal Medicine, he specialised in Neurology with sub-specialty expertise in Movement Disorders and Deep Brain Stimulation. He has sponsored ground-breaking patient-centric Digital Health projects, and designed launches for deep brain stimulation products - from professional education to post market clinical trials.

Binith has been devoted in academic research, at University College London and Oxford University, including basic science and applied clinical research for pain, movement disorders and psychiatric applications. He is the executive sponsor for product development on a first-in-class integrated telemedicine programme solution for neurostimulators which is recently recognized by Time Magazine as one of the 100 best inventions of 2021.

Binith Joseph CHEERAN
Medical and Clinical Affairs
Neurological Therapies, Abbott Labs
 X
Shin-Yuan CHEN
Professor and Chairman, School of Medicine, Tzu Chi University
Director, Centre for Parkinsonism and Related Movement Disorder & Division of Functional Neurosurgery
Department of Neurosurgery, Hualien Tzu Chi Hospital Buddhist Tzu Chi Medical Foundation
Hualien, Taiwan

Shin-Yuan is Professor and Chairman of School of Medicine, Tzu Chi University, Taiwan. He is also Chief of Division of Functional Neurosurgery and Center for Parkinson’s Disease and Movement Disorders of Hualien Tzu Chi General Hospital. He was President of Taiwan Society for Stereotactic Functional Neurosurgery and Radiosurgery in 2014-2015. For more than two decades of being a physician, he dedicated himself to patient care, translational research, mentoring young physicians, hospital administration and medical education. He guides medical students to implement evidence-based practice into patient care. He seeks to overcome research hurdle through multi-disciplinary approach. He has published more than 90 peer-review articles in scientific journals/book chapters.

Not only is he a recognised specialist in the field of Movement-disorders and Neuromodulation, Shin-Yuan is compassionate doctor towards his patients and their families. He found “Taiwan Tulip Movement Disorder Society” in 2007, which is a national based non-profit organization, established for patients with movement disorders and care-givers as a platform and opportunity to hold patient-orientated health symposiums, art exhibitions and outdoor activities.

Shin-Yuan CHEN
Department of Neurosurgery, Hualien Tzu Chi Hospital Buddhist Tzu Chi Medical Foundation
 X
Carol Yim-Lui CHEUNG
Associate Professor
Department of Ophthalmology and Visual Sciences
The Chinese University of Hong Kong, Hong Kong

Dr. Carol Yim-Lui CHEUNG is an Associate Professor at Department of Ophthalmology and Visual Sciences, the Chinese University of Hong Kong. Dr Cheung's main research interest is "imaging of the eye", based on the concept that the eyes are the "window" to the human circulation and nervous systems. She has been working in the field of ocular imaging for more than 15 years in Hong Kong and in Singapore, focus on development and application of image analysis techniques and artificial intelligence for studying diabetic retinal disease, glaucoma and Alzheimer's disease. She is now focused on translating her artificial intelligence-related research from "bench" to "bedside", with an aim to enhance eye and brain diseases screening in primary care, and eye disease triaging in tertiary clinics, for timely disease management and treatment. This will bring significant societal impact by improving quality and efficiency of the clinical service in Hong Kong and beyond the region. Dr Cheung has authored more than 240 original research articles, 9 commentary or editorial articles and 25 review articles in SCI international indexed peer reviewed journals, and 14 book chapters. She has published several landmark papers on development of AI-based technologies in ocular imaging for detection of multiple eye diseases, and using retinal imaging to study Alzheimer's disease, with an H-index of 54 and citations >9,800 (Scopus).

Carol Yim-Lui CHEUNG
Department of Ophthalmology and Visual Sciences
The Chinese University of Hong Kong

 X
Sol T De JESUS
Assistant Professor
Division of Movement Disorders, Department of Neurology
Penn State Milton S. Hershey Medical Center
Pennsylvania, USA

Sol was graduated from the University of Scranton with a major in Neuroscience and minors in Biochemistry and Criminal Justice. She further pursued her medical degree from Ponce School of Medicine. She did her neurology training at Penn State Hershey Medical Center and subspecialty fellowship at University of Florida Movement Disorder Center. Sol is current an Assistant Professor in Department of Neurology and Co-director of the Deep Brain Stimulation Program at the Penn State Hershey Medical Center.

Sol T De JESUS
Division of Movement Disorders, Department of Neurology
Penn State Milton S. Hershey Medical Center
 X
Xiaoling HU
Associate Professor
Department of Biomedical Engineering
The Hong Kong Polytechnic University, Hong Kong

Xiaoling received her PhD in Electronic Engineering from The Chinese University of Hong Kong. Since that time she has been devoting herself in the area of Biomedical Engineering at The Hong Kong Polytechnic University (PolyU). she is currently an Associate Professor in Department of Biomedical Engineering. Her research interests include neural Engineering, multi-module robotic system, biomechatronic Engineering, bio-Signal Processing and Stroke Rehabilitation. She has invented several hybrid robots for stroke rehabilitation, such as neuromuscular electrical stimulation (NMES) and robot hybrid exoskeletons, and mobile exo-neuro-musculo-skeletons. The core patents of the inventions have been licensed out for commercialisation.

Xiaoling serves as reviewer of Annuals of Biomedical Engineering, Biomedical Signal Processing and Control, Clinical Biomechanics, Journal of NeuroEngineering and Rehabilitation, Journal of Applied Biomechanics, Sports Medicine, Arthroscopy, Rehabilitation, Therapy & Technology, and Current Medical Imaging Reviews. She is an associate editor for Journal of NeuroEngineering and Rehabilitation and IEEE Transactions on Neural Systems and Rehabilitation Engineering. She has served as a committee member of IEEE Engineering, Medicine, and Biology Society (EMBS), Hong Kong and Macau Joint Chapter since 2008. She was the programme officer of the Chapter in 2008 and 2009, the secretary in 2010 and 2011, and was the vice chair from 2017 to 2019.

Xiaoling HU
Department of Biomedical Engineering
The Hong Kong Polytechnic University
 X
Harvey Wei HUA
Associate Professor
Department of Neurosurgery
Huashan Hospital, Fudan University
Shanghai, China

Harvey is Associate Professor at Department of Neurosurgery, Hua Shan Hospital, Fudan University in Shanghai. He is a medical graduate of Jilin University in China (2005). He had his neurosurgery specialist training at Hua Sha Hospital, Fudan University where he also obtained his PhD degree (2005) mentored by Professor Liangfu ZHOU. Harvey is specialised in neuro-oncology and immunotherapy and his research interests are epigenetic mechanisms of gliomas and glioblastoma.

Harvey Wei HUA
Department of Neurosurgery
Huashan Hospital, Fudan University

 X
Thomas HUMMEL
Department of Otorhinolaryngology, University of Dresden Medical School, Dresden, Germany

Professor Hummel obtained his medical degree (1986) from the University of Erlangen-Nürnberg, Germany. He received his fellowship training in pharmacology at University of Iowa in USA (1992-93) and went through a special programme (Habilitation) in Pharmacology and Toxicology at University of Erlangen-Nürnberg (1996). He was Assistant Professor at Department of Otorhinolaryngology of University of Iowa in 1996. On his return since 1998 he has been appointed as Professor at Department of Otorhinolaryngology of University of Dresden Medical School, Germany. For his outstanding work in chemosensory systems, he was awarded Takasago Award for excellence in Chemorecption Sciences (1996), Alexander von Humboldt prize from the FNRS Fonds de la Recherche Scientifique, Brussels (2009) and “Professor Dr. Ludwig-Haymann-Preis” of the German ENT Society (2018).

Professor Hummel has published over 750 articles in peer-reviewed journals for a total of 45,800 citations and with an h-index of 105. He is a member of Editorial Boards of internationally recognised journals including European Archives of Otorhinolaryngology, Chemosensory Perception, Allergy & Rhinology, PLoS One, HNO, and ORL (Karger). He is member of European Chemoreception Research Organization, Association for Chemoreception Sciences, International Association for the Study of Pain, American Society for Neuroscience and Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde (German Society for Ear, Nose and Throat Medicine).

Thomas HUMMEL
Department of Otorhinolaryngology, University of Dresden Medical School
 X
Bonaventure Yiu-Ming IP
Assistant Professor
Division of Neurology
Department of Medicine and Therapeutics
The Chinese University of Hong Kong, Hong Kong

Dr. Bonaventure IP obtained his Bachelor of Medicine and Bachelor of Surgery (MBChB) from The Chinese University of Hong Kong. He is a neurology specialist serving as an assistant professor at the Faculty of Medicine, CUHK. Dr. Ip's expertise covers cerebrovascular disease prevention, diagnostics and intervention, he is also a core member of the endovascular neurointervention team of the Prince of Wales Hospital. Dedicated to research and education, Dr. Ip had authored multiple peer-reviewed publications, received the best dissertation award in the 32nd Hong Kong Neurological Society Annual Scientific Meeting (2019) and has been elected as an exemplary teacher and best teacher multiple times by the Faculty.

Bonaventure Yiu-Ming IP
Division of Neurology
Department of Medicine and Therapeutics
The Chinese University of Hong Kong
 X
Jacque Pak Kan IP
Assistant Professor
School of Biomedical Sciences
The Chinese University of Hong Kong, Hong Kong

Prof. Jacque Ip is currently Assistant Professor of the School of Biomedical Sciences at The Chinese University of Hong Kong. Professor Ip is an expert in cutting-edge neurotechnology as well as molecular and system neuroscience. Professor Ip’s research focuses on the mechanisms of synaptic plasticity and how such mechanistic defects result in autism-related disorders. Professor Ip’s work has been published in a number of peer-reviewed journals, including Science, Nature Neuroscience, Nature Review Neuroscience, Molecular Psychiatry, and the Journal of Neuroscience.

Jacque Pak Kan IP
School of Biomedical Sciences
The Chinese University of Hong Kong

 X
Clifford R. JACK
Professor of Radiology and Alexander Family
Professor of Alzheimer's Disease Research
Department of Radiology
Mayo Clinic, Minnesota, USA

The laboratory of Clifford R. Jack Jr., M.D., is engaged in brain imaging research in cognitive aging, Alzheimer's disease and related disorders. Dr. Jack's research team employs MRI and positron emission tomography (PET) to study the biology of brain aging and causes of cognitive impairment and develops image-processing algorithms for quantitatively measuring the information obtained from brain imaging. They employ a variety of MRI-based brain imaging modalities, including structural MRI, spectroscopy, functional connectivity and brain water diffusion. They also employ F-fluorodeoxyglucose positron emission tomography (FDG-PET) and amyloid PET. The lab's clinical imaging research is tightly integrated into the Mayo Clinic Alzheimer's Disease Patient Registry (Mayo Clinic Study of Aging) and Mayo's Alzheimer's Disease Research Center, which conduct National Institutes of Health-funded longitudinal clinical and epidemiological research projects investigating normal aging, Alzheimer's disease and other dementias. Dr. Jack also collaborates with a number of investigators outside Mayo, and his laboratory is the imaging center for several large national multisite studies.

Clifford R. JACK
Aging and Dementia Imaging Laboratory
Mayo Clinic, Minnesota
 X
Paul Sloan LARSON
Professor of Neurosurgery and Chief
Department of Neurosurgery, Southern Arizona VA Health Care System, Arizona, USA

Dr Larson is Professor of Neurosurgery at the University of Arizona and Chief of Neurosurgery at the Southern Arizona VA Health Care System. He is also an associate member of the ASU-Banner Neurodegenerative Diseases Research Center. He specialises in functional neurosurgery, specifically deep brain stimulation for a variety of neurological disorders. Dr. Larson completed medical school at the University of Arizona in 1995, and did his residency training at the University of Louisville. He was a professor in neurological surgery at the University of California, San Francisco from 2001 to 2021.

Dr Larson is a pioneer in the field of interventional MRI-guided stereotaxy for deep brain stimulation (DBS), laser ablation and drug delivery, and has performed well over 1,000 interventional MRI (iMRI) procedures. His clinical research team has been the solo or lead group in 10 gene therapy clinical research trials since 2004, and has the world’s largest experience in intracranial delivery of novel therapeutics for neurodegenerative disorders. Dr. Larson also has a significant interest in the neurobiology of tinnitus. His NIH-funded research in this area has led to the discovery of a new brain region involved in auditory perception.

Paul Sloan LARSON
Department of Neurosurgery, Southern Arizona VA Health Care System
 X
Cindy Xinyi LENG
Assistant Professor
Division of Neurology
Department of Medicine & Therapeutics
The Chinese University of Hong Kong, Hong Kong

Dr. Cindy LENG's research focuses on stroke and intracranial atherosclerotic disease (ICAD). In the past few years, Dr. Leng has been utilizing multimodal neuroimaging and computational methods to study cerebral hemodynamics and plaque characteristics in ICAD and its clinical implications, using a cross-disciplinary approach. She also works on the efficacy and safety of medical and interventional treatment regimens in ischemic stroke, and investigates mechanisms of collateral circulation recruitment and its prognostic values in stroke patients. In these research areas, she has close collaboration with University of Oxford, University of California Los Angeles, Beijing Tiantan Hospital of Capital Medical University, and Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences.

Dr. Leng has been funded by the Research Grants Council of Hong Kong, the Health and Medical Research Fund, National Natural Science Foundation of China, China Association for Science and Technology, World Heart Federation, and the Lee Hysan Postdoctoral Fellowship in Clinical Neurosciences. Since 2013, Dr. Leng has published more than 60 peer-reviewed articles in international academic journals, including Circulation, Annals Neurology, Neurology, J Neurol Neurosurg Psychiatry, Stroke, with an h-index of 18. She is an Associate Editor of Stroke and Vascular Neurology (official journal of Chinese Stroke Association), and serves on the Editorial Board of Stroke (official journal of American Heart Association) and International Journal of Stroke (official journal of World Stroke Organization).

Cindy Xinyi LENG
Division of Neurology
Department of Medicine and Therapeutics
The Chinese University of Hong Kong

 X
Luming LI
Cheung Kong Scholar Chair Professor
Professor of Biomedical Engineering and Neuromodulation technology
Director, National Engineering Research Center of Neuromodulation
Tsinghua University, Beijing, China

Luming is a Tsinghua graduate of 1991 in mechanical engineering. He went on to complete his PhD studentship in 1996 and subsequently excelled in the job as an accomplished academic engineer, working and achieving in his mother university. He did his overseas research fellowship training in the late 1990s in Surrey, England. On returning home to continue his innovation development in engineering, and he was elected Young Scientist of the Nation at the turn of the Century 2000.

Luming is a leader of the field. He is Cheung Kong Scholar Chair Professor and the foundering director of National Engineering Research Center of Neuro-modulation at Tsinghua. He is one of three founders and vice president of Chinese Society of Neuromodulation. He has been concentrating on hardware development of affordable neuromodulation techniques for patient in developing countries. Not only did he invented variable frequency simulation (VFS) for Parkinson’s Disease and other movement disorders, he also invented remote programming techniques, a unique secure web-based remote wireless programming system. The unique device with tele-programming and VFS is widely used in China. He was awarded First Prize of National Science and Technology Progress Award, China, in 2018

Luming LI
National Engineering Research Center of Neuromodulation
Tsinghua University
 X
Yongjie LI
Professor and Co-Director
Centre of Neuro-medicine
The University of Hong Kong - Shenzhen Hospital, Shenzhen, China

Yong-jie is a medical graduate of Beijing University Medical School (1984) and has acquired his PhD. at Shanxi Medical University in 1991. In the mid-1990s, he has done pioneering work in Johns Hopkins and Loma Linda Medical Centres on functional neurosurgery research. On returning home in 1998, he has established the Beijing Functional Neurosurgery Institute at the Xuan-wu Hospital of the Beijing Capitol Medical University. Under his leadership, the number of surgeries for Parkinson's disease and epilepsy both ranked first in the world. Since 2009, Beijing Institute of Functional Neurosurgery has become the world's largest deep brain stimulation (DBS) center. He is has published more than 400 peer-reviewed articles. He is currently Senior Consultant at Division of Neurosurgery, Department of Surgery, and Co-director of Neuro-medical Center of The University of Hong Kong – Shenzhen Hospital.

Yongjie LI
Centre of Neuro-medicine
The University of Hong Kong - Shenzhen Hospital
 X
Vincent Chung-Tong MOK
Endowed Mok Hing Yiu Professor of Medicine
Division of Neurology
Department of Medicine and Therapeutics
The Chinese University of Hong Kong, Hong Kong

Professor Vincent C.T. MOK 's research aims to understand mechanisms of dementia and to investigate strategies that may help to prevent dementia. He is the first to report the association of cerebral small vessel disease (CSVD) and cognitive impairment in Asia and the first to report the community prevalence of CSVD among Asians (Chinese). Such findings have significantly increased the awareness that strategies targeting CSVD (e.g. blood pressure lowering) can help to prevent dementia in this region, where the burden of dementia is particularly huge. Prof. Mok conducted one of the largest single-centre studies investigating the prevalence and mechanisms of early and delayed cognitive decline in the context of stroke and found that concurrent presence of amyloid plaques as detected by in-vivo amyloid PET imaging and CSVD are important factors associated with early and delayed cognitive decline after stroke, respectively. Such findings provide a road map of how to prevent vascular cognitive impairment. Prof. Mok, along with Dr Adrian Wong (Clinical Psychologist) validated the Hong Kong-Montreal Cognitive Assessment (HK-MoCA) and developed norms for HK-MoCA performance according to age and education. HK-MoCA is currently the commonest brief cognitive assessment used for the assessment of cognitive function and the detection of mild cognitive impairment in HK.

Prof. Mok has been involved in the validation and clinical application of a novel Machine-Learning MRI-based Index, which was developed by a spin-off company of the Chinese University of Hong Kong (CUHK), for the detection of early Alzheimer's disease. Such technology provides an easy screening method for early Alzheimer's disease among subjects with mild cognitive impairment. Moreover, he also specializes in Parkinson's disease and was one of the pioneers of developing Deep Brain Stimulation programme in Asia for the treatment of Parkinson's disease. He received the Higher Education Outstanding Scientific Research Output Award (Science & Technology) in Natural Sciences (1st Class) from the Ministry of Education, People's Republic of China in 2011 for his research in cerebrovascular disease, Outstanding Fellow Award from the Faculty of Medicine of CUHK for his exceptional academic leadership in areas of research, education and service in 2016, Endowment as Mok Hing Yiu Professor of Medicine by CUHK in 2017, and the Excellent Research Award from the Food and Health Bureau of the Hong Kong Special Administrative Region for his research in vascular cognitive impairment in 2017. He received 7 times Teacher of the Year Award and the Master Teacher Award from the Faculty from the Faculty of Medicine, CUHK.

Prof. Mok has authored more than 300 publications in peer-reviewed international journals (with book chapters), with publications at Lancet, JAMA, Lancet Neurology, Nature Reviews Neurology, Alzheimer's & Dementia, JAMA Neurology, JAMA Psychiatry, Journal of Neurology, Neurosurgery and Psychiatry (JNNP), Annals of Neurology, Neurology and Stroke.

Vincent Chung-Tong MOK
Division of Neurology
Department of Medicine and Therapeutics
The Chinese University of Hong Kong

 X
Ho-Keung NG
Professor
Department of Anatomical and Cellular Pathology
The Chinese University of Hong Kong, Hong Kong

H.K. is Chair Professor at CUHK. His interests are in the molecular pathology of brain tumours, both adult and paediatric. H.K. is both a neuropathologist and general pathologist. He is an Associate Editor of Laboratory Investigation and an Associate Editor of Neuro-Oncology Advances, and is also on the Editorial Boards of Acta Neuropathologica, Brain Pathology, Neuropathology and Applied Neurobiology, Clinical Neuropathology, Pathology and International Journal of Clinical and Experimental Pathology. He was a member of the Consensus Group of the 2007 and 2016 WHO classifications of the brain tumours. And for the upcoming WHO 2020, he is one of the only 10 neuropathologists from around the world selected to make up the Consensus Group.

H.K. was part of the team who received The 2nd Tier Prize of The National Science and Technology Award of China in 2010 and the First Tier Prize of the Science and Technology Award of Shanghai in 2019. He received The International Academy of Pathology Gold Medal twice in 2006 and 2017.

Ho-Keung NG
Department of Anatomical and Cellular Pathology
The Chinese University of Hong Kong
 X
Wai-Sang POON
Emeritus Professor
Division of Neurosurgery
Department of Surgery
The Chinese University of Hong Kong, Hong Kong

Wai is a Glasgow medical graduate of 1978 and trained in Neurosurgery at Glasgow's Institute of Neurological Sciences [1983-1986]. He did his research fellowship at Department of Neurosurgery, Massachusetts General Hospital/ Harvard Medical School in 1990-1991. He has joined The Chinese University of Hong Kong (CUHK)/ Prince of Wales Hospital (PWH) as a faculty member in academic neurosurgery since 1986 and became Chief in Neurosurgery [1988-2019] and Chair Professor in 2003. He is currently Emeritus Professor and Clinical Professional Consultant, and Director of the CUHK Otto Wong Brain Tumour Centre.

Wai has a strong interest in clinical and experimental head injury, and more recently cell therapy, cell biology in brain tumours and axonal injury in central nervous system. He has the expertise and motivation to do prospective clinical studies as Principle Investigator in brain injuries. He is author of 450 peer-reviewed publications.

Wai is an active participant of college and society activities locally and internationally. He has been doing medico-legal work since 1992. He is active in undergraduate and postgraduate surgical education, and specialist training in Neurosurgery, as Vice President [Internal Affairs] of The College of Surgeons of Hong Kong (CSHK), Chief Examiner for Neurosurgery and Past Chairman of the Neurosurgery Board [2007-2019] of the CSHK.

Wai-Sang POON
Division of Neurosurgery, Department of Surgery
Prince of Wales Hospital/ The Chinese University of Hong Kong
 X
Vinay K. PUDUVALLI
Professor and Chair
Department of Neuro-oncology
The University of Texas M. D. Anderson Cancer Center, Houston, USA

Dr. Vinay K. Puduvalli is Chair of Neuro-Oncology at The University of Texas MD Anderson Cancer Center, Co-director of the Brain Tumor Center, Co-leader of the Glioblastoma Moon Shot® and Leader of the Brain Cancer Program of the CCSG. He is an authority on developing novel therapies for patients with primary brain tumors.

He earned his medical degree from Bangalore Medical College, followed by residency in neurology at The University of Texas Health Sciences Center in Houston and fellowship in Neuro-Oncology at MD Anderson. He served as Professor and Director of Clinical Research of Neuro-Oncology and led the Neuro-oncology Fellowship Program at MD Anderson. In 2013, he was recruited to the Ohio State University Comprehensive Cancer Center to serve as Director of Division of Neuro-oncology where he held the Sanford and Rife Family Endowed Chair in Neuro-Oncology and was instrumental in establishing a multidisciplinary brain tumor center in that institution. He was recruited back to MD Anderson in 2020 to assume the position of Dhair of the Department of Neuro-oncology.

Dr. Puduvalli’s research focuses on developing new treatments for brain malignancies using a combined approach of targeted therapies, innovative clinical trial designs and rational combinations of anticancer agents. His laboratory research focuses on identifying vulnerabilities in gliomas in order to target these with novel agents using a variety of pre-clinical models. His research has uncovered various mechanisms of tumor sensitivity and resistance to such agents, examined the role of epigenetics in brain tumor and glioma stem cell biology, and translated these findings to new treatment options. His team has also identified novel ways to target stress response and energy metabolism in gliomas to specifically target tumor cells while sparing normal ones. In this context, he has led several multicenter clinical studies involving epigenetic therapies and novel targeted agents. His awards include recognition in America’s Top Doctors and America’s Top Doctors for Cancer.

Vinay K. PUDUVALLI
Department of Neuro-oncology
The University of Texas M. D. Anderson Cancer Center

 X
Filip SCHEPERJANS
Attending Neurologist
Clinical Research Group Leader
Department of Neurology
Helsinki University Hospital, Helsinki, Finland

Dr. Filip SCHEPERJANS, MD, studied medicine at the University of Düsseldorf (Germany) and gained international experience as a visiting student in London, New York, and Helsinki. His doctoral thesis in the field of neuroanatomy under Prof. Karl Zilles (C & O Vogt Institute for Brain Research, University of Düsseldorf and Institute of Medicine, Research Center Jülich, Germany) was awarded the best medical thesis of the University of Düsseldorf in 2008. Now living in Finland, he works as attending neurologist and clinical research group leader at the Department of Neurology of Helsinki University Hospital. He is adjunct professor of neurology at the University of Helsinki and his clinical and research focus are movement disorders. He pioneered the research on gut microbiota in Parkinson’s disease through the first publication ever to assess gut microbiota composition in Parkinson’s vs. control subjects. Since then, he has published numerous high impact papers further elucidating how gut microbiota interact with the host and impact Parkinson’s symptoms and progression. His research group is currently conducting a first randomized double-blind controlled trial of fecal microbiota transplantation in PD. His work has led to several patents that are currently the basis for the development of next generation bacterial diagnostics and treatments for Parkinson’s through his company NeuroBiome Ltd. For his groundbreaking work in this field, he was awarded the Uschi Tschabitscher Prize for Young Neurologists by the European Academy of Neurology in 2014, the young researcher award of the Finnish Neurological Society in 2019, and the Research Prize of the Wilhelm and Else Stockmann Foundation in 2021.

Filip SCHEPERJANS
Department of Neurology
Helsinki University Hospital
 X
Sophie SCOTT
Professor of Cognitive Neuroscience
Leader of the Speech Communication Group
Institute of Cognitive Neuroscience
University College London, United Kingdom

Prof. Sophie SCOTT is currently Professor of Cognitive Neuroscience and Leader of the Speech Communication Group of the Institute of Cognitive Neuroscience at University College London. Professor Scott is also a member of the British Psychological Society, the Society for Neuroscience, the Cognitive Neuroscience Society, and the Experimental Psychology Society. In 2012, she was elected a Fellow of the Academy of Medical Sciences. In 2016, she was elected a Fellow of the British Academy. Professor Scott is a renowned expert in the cognitive neuroscience of speech perception, speech production, vocal emotions, and human vocal communication. Professor Scott’s research focuses on how our brains process the information in speech and voices and how our brains control the production of our voices. She is interested in dyslexia and the individual differences and plasticity in speech perception.

Sophie SCOTT
Institute of Cognitive Neuroscience
University College London
 X
Martin J. van den BENT
Professor of Neuro-oncology
Erasmus University, Rotterdam, The Netherlands
Head, Neuro-oncology Unit, Daniel den Hoed Cancer Center/ Erasmus MC Cancer Institute
University Medical Center Rotterdam, The Netherlands

Martin serves as Head of the Neuro-Oncology Unit of the Daniel den Hoed Cancer Center at Erasmus University Medical Center (Erasmus MC) in the Netherlands. He obtained his medical degree (1983) from the Vrije Universiteit, Amsterdam and completed his neurology and neurosurgery training at Hervormd Diaconessenhuis, Arnhem (1984), and at St Lucas Ziekenhuis, Amsterdam where he also received clinical neurophysiology training (1991). He has joined Erasmus MC since 1992 and became Professor of Neuro-oncology in 2006.

Martin has been the Principle Investigator in many international multicentre phase II and III trials on both high- and low-grade glial tumors. His other research interests include prognostic markers in neuro-oncology and genetic changes that occur in brain tumors. He is the recipient of a number of research grants on primary brain tumours. He was awarded for Excellence in Clinical Research/ Adult Clinical Research three times by the Society of Neuro-Oncology, USA (2004, 2014 and 2018). He was the recipient of the European Cancer Organisation Clinical Research Award in 2015. He has written extensively on primary brain tumors and his articles have appeared in peer-reviewed journals such as Journal of Clinical Oncology, New England Journal of Medicine, Lancet, Lancet Oncology and Neuro-oncology.

Martin served as the Chair of the European Organization of Research and Treatment of Cancer (EORTC) Brain Tumor Group in 2003-2009. He was the President of the European Association of Neuro-Oncology (EANO) in 2018-2020 and currently is the Chair of EANO Guideline Committee. He has served on a number of neuro-oncology committees/ working groups, data safety boards, monitoring committees and steering committees of cancer trials.

Martin J. van den BENT
Daniel den Hoed Cancer Center/ Erasmus MC Cancer Institute
University Medical Center Rotterdam

 X
Jiguang WANG
Padma Harilela Associate Professor of Life Science
Division of Life Science & Department of Chemical & Biological Engineering
The Hong Kong University of Science & Technology, Hong Kong

Jiguang is an endowed Associate Professor in Division of Life Science and Department of Chemical and Biological Engineering of HKUST. He received his PhD degree in applied mathematics from Academy of Mathematics and Systems Science, Chinese Academy of Sciences (CAS), and won the Special Prize of President Scholarship and Excellent PhD thesis Award of CAS in 2011. Between 2011 and 2015, he was a Postdoctoral Research Scientist in Department of Biomedical Informatics at Columbia University. From 2015, he was named as the Precision Medicine Fellow and promoted to an Associate Research Scientist.

Jiguang established the Wang Genomics Laboratory at HKUST in 2016, focusing on the application of data science technology in brain cancer genomics and medicine. He won the Excellent Young Scientist Award of NSFC (2019), School of Engineering Young Investigator Research Award (2019), School of Science Research Award (2021), and the Zhong Nanshan Youth Science and Technology Innovation Award (2021). His research interests are focusing on discovering and elucidating functional genomic alterations in complex human diseases, such as intracranial cancers and vascular malformations, by developing and/or applying computational methods based on multi-omics integration, statistics, and machine learning, aiming to bridge the gaps among data, bench, and bedside.

Jiguang WANG
Division of Life Science & Department of Chemical & Biological Engineering
The Hong Kong University of Science & Technology
 X
Yun Kwok WING
Professor (Clinical) & Chairman
Department of Psychiatry
The Chinese University of Hong Kong, Hong Kong

Prof. Yun Kwok WING graduated from The Chinese University of Hong Kong, Hong Kong SAR, China. He is currently the Chairman and Professor in the Department of Psychiatry of the Faculty of Medicine of the Chinese University of Hong Kong. He is also the Director of the Li Chiu Kong Family Sleep Assessment Unit of The Chinese University of Hong Kong.

Professor Wing has diverse research interest in sleep and circadian medicine, psychiatric disorders, neuropsychiatry, and transcultural psychopharmacology. He has active contribution to the scientific communities, including his leadership role in the Hong Kong Society of Sleep Medicine (ex-President, HKSSM) and Asian Sleep Society of Sleep Medicine (ASSM, Vice-president of Education). He was also involved in the World Association of Sleep Medicine (Scientific Committee, 2011, 2013 and 2015), World Sleep 2017, 2019 and 2022 (Scientific Committee). He has recently organised and chaired the Gordon Research conference on the "Cognitive Dysfunction in Brain diseases" in Hong Kong May 2019. He is currently serving at 6 editorial boards including his role as Associate Editor in the journal 'Behavioral Sleep Medicine' and Deputy Editor in 'Sleep Medicine Research'.

He and his research group has established the first local epidemiological data of various sleep disorders including sleep deprivation, insomnia, narcolepsy, and parasomnia. In particular, the group has studied interaction of sleep and circadian propensity with psychiatric disorders and has recently completed a study on using bright light adjuvant treatment to manage patients with depression and evening chronotype. The group has also completed a novel prevention study of insomnia among at-risk adolescents. In addition, the group has extensive work on REM Sleep behavioral disorder, a sleep disorder with high specificity in predicting future alpha-synucelinopathy neurodegeneration. Our recent familial RBD study suggested a strong familial aggregation and staging pathology of alpha-synucleinopathy. The group is working on the brain-gut hypothesis at which the microbiota may have a significant role in predisposing to future synucleinopathy as well as the close relationship among psychiatric disorders, RBD and alpha-synucleinopathy.

Professor Wing was awarded the distinguished national award for Sleep Medicine Scientific Technological Advance in China by the Chinese Medical Doctor Association at 2010 and distinguished contributions to the development of sleep medicine and sleep research by Chinese Sleep Research Society at 2016. He was also awarded the Teacher of the Year Awards, Faculty of Medicine, CUHK in 2012-13.

Yun Kwok WING
Department of Psychiatry
The Chinese University of Hong Kong
 X
Peter Yat Ming WOO
Associate Consultant
Department of Neurosurgery
Kwong Wah Hospital
Hong Kong, China

Peter is a 2004 medical graduate of The University of Hong Kong where he has obtained a Master degree in Medical Science (2010). He received the First Prize of Research of the Year Award from The College of Surgeons of Hong Kong and the First Prize of Higher Surgical Trainee Paper Presentation from the Hong Kong Neurosurgery Society during his Neurosurgical Training. He was qualified as Specialist Neurosurgeon in 2013. He subsequently matures in different areas: (1) neuro-oncology, (2) an elected member of the Specialty Board in Neurosurgery, a voice for the young neurosurgeons, and (3) prolific writer in brain tumours and emergency neurosurgery. Peter is currently Associate Consultant at Department of Neurosurgery, Kwong Wah Hospital and President of The Hong Kong of Neuro-oncology Society.

Peter Yat Ming WOO
Department of Neurosurgery
Kwong Wah Hospital

 X
Angela Ruohao WU
Assistant Professor
Division of Life Science & Department of Chemical & Biological Engineering
The Hong Kong University of Science & Technology, Hong Kong

Angela is an Assistant Professor at Division of Life Science and Department of Chemical and Biological Engineering, and Assoicate Director of Center for Epigenomics Research, The Hong Kong University of Science and Technology. She was graduated with a bachelor degree in Bioengineering from University of California, Berkeley. She further pursued her MS and PhD degrees and did her post-doctoral fellowship at Stanford University.

Angela is one of the first scientists in the world to work in single cell genomics and low-cell-number epigenomics. She pioneered the field of microfluidic chromatin immunoprecipitation (ChIP) by designing the first microfluidic device for automated studies that extended the limits of sensitivity down to 2,000 cells. Her seminal work in characterization of single-cell RNA sequencing remains a benchmark for single-cell RNA-seq analysis in the field. She is a recognized innovator in the genomics and microfluidics fields. Her current research is highly interdisciplinary and applies genomics and microfluidics to solve complex biological questions. She and her team are developing innovative technological platforms for precise cellular analysis and manipulation, as well as translating genomics solutions into the clinic.

Angela Ruohao WU
Division of Life Science & Department of Chemical & Biological Engineering
The Hong Kong University of Science & Technology
 X
Hannah Hong XUE
Professor Emeritus
Adjunct Professor
Division of Life Science and Institute for the Environment & HKUST Fok Ying Tung Graduate School
The Hong Kong University of Science & Technology, Hong Kong

Hannah obtained her MD from the Shanghai Second Military Medical University in 1983, PhD from the Institute of medical Sciences, University of Toronto in 1992, and carried out postdoctoral studies at the Department of Genetics, University of Glasgow before joining the Department of Biochemistry, HKUST in 1994. She was awarded the 2005-2006 Croucher Senior Research Fellowship and the 2010 Higher Education Outstanding Scientific Research Output Award (Science and Technology) in Natural Sciences. Currently, Hannah is a Professor Emeritus at Division of Life Science, HKUST, and Adjunct Professor and Director of Center for Cancer Genomics at China Pharmaceutical University.

Hannah’s group research focuses on genomics, bioinformatics and evolution biology to decipher the mechanisms of human complex disorders. The group is also interested in translational research on novel therapeutics and diagnostics for complex diseases such as neuropsychiatric disorders.

In 2003, Hannah and her team discovered the association between schizophrenia and a segment of the GABRB2 gene encoding the beta-2 subunit of GABA-A receptors. These discoveries represent therefore the first instance where a schizophrenia-susceptibility gene has been linked to protein processing and further to electrophysiological response of neurons, thereby opening the door toward understanding the mechanism of schizophrenia etiology leading from gene to neuronal phenotype.

Hannah is a member of the International Cancer Genome Consortium. She is leading the brain metastatic cancer genomics efforts in Hong Kong in collaboration with Mainland scientists and clinicians. With supports from Innovation and Technology Fund and the University Grant Council, HKSAR, her research group has developed an effective method, AluScan and dedicated bioinformatics algorithms for genome wide scanning of sequence and structure variations. In collaboration with clinical scientists from Hong Kong and the Mainland, her research group has reported massive interstitial loss-of-heterozygosity as evidence of cancer being a disease of DNA damage response, and forward-reverse mutations at stages of cancer development. Along with novel genomic markers developed by her group, AluScan has been demonstrated highly effective in cancer survival prognosis. Recently, her group has reported Daughter Number Variations (DNVs) as a new type of somatic variations, in addition to known types of variations in forms of Single Nucleotide Variations (SNVs) and Copy Number Variations (DNVs).

Hannah Hong XUE
Division of Life Science and Institute for the Environment & HKUST Fok Ying Tung Graduate School
The Hong Kong University of Science & Technology
 X
Peter J. YOO
Director (Product Management)
Deep Brain Stimulation (DBS) Portfolio
Boston Scientific
California, USA

Peter is the Director of Product Management overseeing the Deep Brain Stimulation (DBS) portfolio at Boston Scientific. Peter and his team have driven the development and release of multiple generations of DBS hardware and software over the last decade and continue to work to improve therapy solutions for clinicians and patients worldwide.

Peter J. YOO
Deep Brain Stimulation (DBS) Portfolio
Boston Scientific

 X
Zhenyu ZHANG
Associate professor
Secretary of Scientific Research
Department of Neurosurgery, First Affiliated Hospital of Zhengzhou University
Zhengzhou, China

Zhenyu is an Associate Professor and Secretary of Scientific Research at Department of Neurosurgery, The First Affiliated Hospital of Zhengzhou University. His research interests are artificial intelligence of central nervous system tumours, radio-genomics of gliomas and molecular pathology of gliomas/ medulloblastoma.



PROGRAMME

The Conference Hours:
Hong Kong
25 Feb 2021, Friday 09:00 - 18:00
26 Feb 2021, Sat 09:00 - 15:30
  Australia Sydney
25 Feb 2022, Friday 12:00 - 21:00
26 Feb 2022, Sat 12:00 - 18:30
Central Europe
25 Feb 2022, Friday 02:00 - 11:00
26 Feb 2022, Sat 02:00 - 08:30
  United States California
24 Feb 2022, Thursday 17:00 - 02:00 (+1)
25 Feb 2022, Fri 17:00 - 23:30
United States Minnesota
24 Feb 2022, Thursday 19:00 - 04:00 (+1)
25 Feb 2022, Fri 19:00 - 21:30
   
*All communicated times in the Scientific Programme are Hong Kong Time. Hong Kong is 8 hours ahead of Greenwich Mean Time (i.e. GMT+8 hours).

Time / Date 24 Feb 2022 (Thursday) 25 Feb 2022 (Friday) 26 Feb 2022 (Saturday)
0800-0830   Registration
0830-0900
0900-0930 Session 1
Stroke
(Webinar A)
Session 5A
Transforming Imaging for Alzheimer's Disease
(Webinar A)
Session 5B
Brain Tumours II
(Webinar B)
0930-1000
1000-1030
1030-1100 Intermission
1100-1130 Session 2
Brain Tumours I
(Webinar A)
Intermission
1130-1200 Session 6A
Abstract Oral Presentation I - Clinical Research
(Webinar A)
Session 6B
Parkinson's Disease - DBS System & Technology
(Webinar B)
1200-1230
1230-1300 Intermission Intermission
1300-1330 Intermission Session 7
Abstract Oral Presentation II - Basic Research
(Webinar A)
1330-1400
1400-1430 Session 8
Mr Otto Lien Da Wong Visiting Professorial Lecture in Neuro-Oncology
(Webinar B)
1430-1500 Satellite Symposium
Hong Kong Student Association of Neuroscience
(Webinar A)
Session 3
Parkinson's Disease - Pre-motor Symptoms
(Webinar A)
1500-1530
1530-1600  
1600-1630   Intermission
1630-1700 Session 4
Parkinson's Disease - Evolving Technology of DBS
(Webinar A)
1700-1730
1730-1800
1800-1830
24 Feb 2022 (Thursday)

Roundtable Session: Cognitive Neuroscience
Chairpersons : Safari CHIU & Serena YU
Webinar A
14:30 Welcome Address
14:35 The Neural Basis of Sound Processing - Implications for the Perception of Speech Sophie SCOTT
15:05 Probing Synaptic and Plasticity Deficits in Neurodevelopmental Disorders Jacque Pak Kan IP
15:35 Panel Discussion
15:55 Conclusion
25 Feb 2022 (Friday)

Session 1 : Stroke
Chairpersons : FONG Wing-chi & Yannie SOO
Webinar A
09:00 Mobile Exoneuromusculoskeleton for Telerehabilitation after Stroke Xiaoling HU
09:30 Cerebral Hemodynamics in Intracranial Atherosclerotic Disease Cindy LENG
10:00 Direct Oral Anticoagulants - Insights from International and Local Real World Data Bonaventure IP
10:30 Intermission

Session 2 : Brain Tumours I
Chairpersons : Herbert H.F. LOONG & Peter Y.M. WOO
Webinar A
11:00 Hong Kong Lower-grade Glioma Registry Peter Y.M. WOO
11:20 Molecular Pathology of IDH Mutant Gliomas: The Unanswered Questions Ho-Keung NG
11:40 Prediction of Molecular Pathology in Glioma from MRI Using AI Zhenyu ZHANG
12:00 Translational Therapy of Gliomas - Looking Beyond Conventional Targets Vinay K. PUDUVALLI
12:30 Trials of CODEL & CATNON and the Up-to-date Standard of Care Treatment Martin J van den BENT
13:00 Intermission

Session 3 : Parkinson's Disease - Pre-motor Symptoms
Chairpersons : Germaine H.F. CHAN & Vincent C.T. MOK
Webinar A
14:30 REM Sleep Behavioral Disorder and α- Synucelinopathy - A Window to Prevent Neurodegeneration Yun Kwok WING
15:00 Gastrointestinal Dysfunction and Microbiota in Parkinson's Disease Filip SCHEPERJANS
15:30 Olfactory Function in Parkinson's Disease Thomas HUMMEL
16:00 Intermission

Session 4 : Parkinson's Disease - Evolving Technology of Deep Brain Stimulation (DBS)
Chairpersons : Michael W.Y. LEE, Wai S. POON & Tak-Lap POON
Webinar A
16:30 A Tale of Two Frames - from Leksell G to Leksell Vantage Danny T.M. CHAN
16:50 Directional Deep Brain Stimulation under General Anesthesia Shin-Yuan CHEN
17:10 Application of Intraoperative CT in Robot-Assisted Deep Brain Stimulation Xiaodong CAI
17:30 Interventional MRI (iMRI) - guided Deep Brain Stimulation (DBS) Paul S. LARSON
18:00 Movement disorders and Their Stereotactic Surgical Treatment: A Retrospective Study of 5126 Patients at a Single Clinical Center over 22 Years Yongjie LI
26 Feb 2022 (Saturday)

Session 5A : Alzheimer's Disease
Theme: Transforming Imaging for Alzheimer's Disease
Chairpersons : Vincent C.T. MOK & Jill ABRIGO
Webinar A
09:00 A Biological Definition of Alzheimer's Disease: NIA-AA Research Framework Present and Future Clifford R. JACK
09:40 Machine Learning Derived Biomarker Based on MRI for Alzheimer's Disease Vincent MOK
10:05 Retinal Biomarkers for Alzheimer's Disease Carol CHEUNG
10:30 Chemical Exchange Saturation Transfer (CEST) MRI for Alzheimer's Disease Kannie CHAN
10:55 Intermission

Session 5B : Brain Tumour II
Chairpersons : Danny T.M. CHAN & Ho-Keung NG
Webinar B
09:00 scONE-seq: A One-tube Single-cell Multi-omics Method Enables Simultaneous Dissection of Molecular Phenotype and Genotype Heterogeneity from Frozen Tumors Angela R. WU
09:30 Identification of Early Predictors of Glioblastoma Evolution under Therapy Jiguang WANG
10:00 The Epigenetic Mechanism and Clinical Translation of Metabolic Profiling in IDH Mutated Gliomas Harvey W. HUA
10:30 Non-mitotic Mode of Proliferation in Primary Cancer Cells and Cell Lines Hannah H. XUE
11:00 Intermission

Session 6A : Abstract Oral Presentation I - Clinical Research
Chairpersons : Thomas W. H. LEUNG & David Y.C. CHAN
Webinar A
11:15 Stronger Association was shown between Cognition with Pulsatility Index than with Conventional Imaging Markers in Community Elderly without Dementia Maggie L.M. LAM
11:25 Application of Pre-Hospital Identification and Notification of Stroke Patients (Pre-act) Initiative to the Management of Haemorrhagic Stroke Queenie H.W. WONG
11:35 Dynamic Changes in Automatic Generated Quantitative Biomarkers - A Longitudinal Study Xiang FAN
11:45 Biomarkers for the Detection of Progressive Early Alzheimer's Disease Vera CAI
11:55 Glioblastoma Patient Survival Predictors treated by the Hong Kong Hospital Authority: A Multicenter Retrospective 15-year Review Chi Chun LAM
12:05 Integrative Medicine as an Alternative Approach to Reduce Fatigue and Inflammation in Multiple Sclerosis Angel NG
12:15 A Novel Brain Biopsy Cannula for Safe and Adequate Tissue Acquisition Yitian XIAN
12:25 Mapping Structural Disconnection to Behavioral Dysexecutive Symptoms in Subcortical Stroke Lisha WANG
12:35 Intermission

Session 6B : Parkinson's Disease - DBS System & Technology
Chairpersons : Fung-Ching CHEUNG, Benedict B.T. TAW & Xian-Lun ZHU
Webinar B
11:30 The Development of DBS Device in China and Future Direction Luming LI
11:50 Clinical Application of Directional Lead and Virtual Clinic to DBS Patients Binith J. CHEERAN
12:10 Personalised DBS Programming: Delivering Patient Specific Stimulation by Combining High-resolution Stimulation Control with Image Guided Programming Capabilities Peter J. YOO
12:30 Workflow Considerations for BrainSense Technology Sol T. De JESUS
12:50 Discussion  
13:00 Intermission

Session 7 : Abstract Oral Presentation II - Basic Research
Chairperson: Owen H. Ko
Webinar A
12:45 The Spatial and Temporal Dynamics of Microglia Cells Following Transient Focal Cerebral Ischemia Cyrus W. C. CHENG
12:55 Cell Cycle Associated Transcription Factors Regulate Neuroinflammation in Alzheimer's Disease Yi ZHANG
13:05 Preliminary Evaluation of the Therapeutic Potential of MIR-30C MIMIC Treatment in Acute Ischemic Stroke: Dose-Response and Therapeutic Time Window Rong JIN
13:15 Closing Remarks

Session 8 : Mr Otto Lien Da Wong Visiting Professorial Lecture in Neuro-oncology
Webinar B
14:00 Current Management of Atypical Glioma Martin J van den BENT
15:00 Closing Remarks
Poster Presentation
THE SPATIAL AND TEMPORAL DYNAMICS OF MICROGLIA CELLS FOLLOWING TRANSIENT FOCAL CEREBRAL ISCHEMIA
CYRUS WING CHUNG CHENG
RETURN-TO-WORK PROGRAM FOR STROKE SURVIVORS: A PILOT STUDY
MING KIT LAI
BIOPSY OF PAEDIATRIC BRAINSTEM INTRINSIC TUMOURS: EXPERIENCE FROM A SINGAPORE CHILDREN’S HOSPITAL
SHARON LOW

ADJUNCTIVE PERAMPANEL EFFECTIVENESS AND TOLERABIITY FOR DRUG RESISTANT EPILEPSY IN HONG KONG
CHARLIE CHAN
PREVALENCE OF SEIZURES IN OLIGODENDROGLIOMA: A SYSTEMATIC REVIEW AND METAANALYSIS
CHRISTINE AUDREY
STRONGER ASSOCIATION WAS SHOWN BETWEEN COGNITION WITH PULSATILITY INDEX THAN WITH CONVENTIONAL IMAGING MARKERS IN COMMUNITY ELDERLY WITHOUT DEMENTIA
MAGGIE LI MAN LAM

APPLICATION OF PRE-HOSPITAL IDENTIFICATION AND NOTIFICATION OF STROKE PATIENTS (PRE-ACT) INITIATIVE TO THE MANAGEMENT OF HAEMORRHAGIC STROKE
QUEENIE HOI WING WONG
GENDER DISPARITY IN THE INCIDENCE OF CHILDHOOD CENTRAL NERVOUS SYSTEM CANCERS AMONG DIFFERENT ASIAN PACIFIC ISLANDER POPULATIONS
ALISTAIR LAM
THE EXPLANATIONS OF THE BIAS IN MACHINE LEARNING-INFORMED BRAIN AGE PREDICTION FROM A PERSPECTIVE OF BRAIN RESILIENCE
JING LI

APPLICATION OF 3D PRINTING AND HYBRID REALITY SURGICAL PLANNING REAL-TIME NAVIGATION SYSTEM IN NEUROTUMOR SURGERY
JIANTAO LV
ALZHEIMER'S DISEASE RESEMBLANCE ATROPHY INDEX (AD-RAI) IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE – A PHASE 2 VALIDATION MULTI-DATABASE STUDY
XIANG FAN
ASSOCIATION BETWEEN ALZHEIMER'S DISEASE (AD) RESEMBLANCE ATROPHY INDEX (AD-RAI) AND QUANTITATIVE HIPPOCAMPUS-RELATED MRI BIOMARKERS WITH AGE AND GENDER AMONG OLDER NORMAL INDIVIDUALS
XIANG FAN

DYNAMIC CHANGES IN AUTOMATIC GENERATED QUANTITATIVE BIOMARKERS - A LONGITUDINAL STUDY
XIANG FAN
IMPACT OF ANTI EPILEPTICS ON SURVIVAL IN PATIENTS WITH GLIOMA
THINISHA SATHIS
ASSOCIATION BETWEEN AMYLOID, TAU AND CEREBRAL SMALL VESSEL DISEASE
VERA CAI

BIOMARKERS FOR THE DETECTION OF PROGRESSIVE EARLY ALZHEIMER’S DISEASE
VERA CAI
GLIOMA LIQUID BIOPSY BY APPLYING MACHINE LEARNING TO SUBSETS OF EXTRACELLULAR VESICLES
ABHIMANYU THAKUR
DEVELOPMENT OF MACHINE LEARNING INTEGRATED DEXTERITY MODEL FOR NEURODEGENERATIVE DISEASE
SUDHA THAKUR

EFFECTS OF ACUPUNCTURE UPON CEREBRAL PERFUSION IN CEREBRAL SMALL VESSEL DISEASE: A PILOT STUDY
CHUN HUNG TANG
CELL CYCLE ASSOCIATED TRANSCRIPTION FACTORS REGULATE NEUROINFLAMMATION IN ALZHEIMER’S DISEASE
YI ZHANG
AN MRI-BASED MACHINE LEARNING DERIVED BIOMARKER IN DIFFERENTIATING FRONTOTEMPORAL DEMENTIA FROM ALZHEIMER'S DISEASE
VERA CAI

GLIOBLASTOMA PATIENT SURVIVAL PREDICTORS TREATED BY THE HONG KONG HOSPITAL AUTHORITY: A MULTICENTER RETROSPECTIVE 15-YEAR REVIEW
CHI CHUN LAM
INTEGRATIVE MEDICINE AS AN ALTERNATIVE APPROACH TO REDUCE FATIGUE AND INFLAMMATION IN MULTIPLE SCLEROSIS
ANGEL NG
IS RE OPERATION WORTHWHILE IN GBM PATIENTS WITH RECURRENCE?
WAN MUHAMMAD AFNAN

A NOVEL BRAIN BIOPSY CANNULA FOR SAFE AND ADEQUATE TISSUE ACQUISITION
YITIAN XIAN
MAPPING STRUCTURAL DISCONNECTION TO BEHAVIORAL DYSEXECUTIVE SYMPTOMS IN SUBCORTICAL STROKE
LISHA WANG
PRELIMINARY EVALUATION OF THE THERAPEUTIC POTENTIAL OF MIR-30C MIMIC TREATMENT IN ACUTE ISCHEMIC STROKE: DOSE-RESPONSE AND THERAPEUTIC TIME WINDOW
RONG JIN

DKK3 PLAYS A CRITICAL ROLE IN ISCHEMIC BRAIN DAMAGE AND PULMONARY EMBOLISM AFTER FOCAL CEREBRAL ISCHEMIA/REPERFUSION IN MICE
RONG JIN
MASS SPECTROMETRY-BASED METABOLOMICS FOR THE INVESTIGATION OF BIOMARKERS IN PARKINSON’S DISEASE
XIAOXIAO WANG

Should there be any questions to the authors, please send your questions to brainconference@cuhk.edu.hk. Thank you.

*The programme may be subject to change without prior notice.

REGISTRATION

Free Registration
In order to make BRAIN 2022 more accessible, this year's conference is free to join.

Your health and safety is our priority
To safeguard the health, safety and wellbeing of the speakers, delegates and sponsors at BRAIN 2022, the Conference will be held in virtual format.

ABSTRACTS

Authors are invited to submit abstracts on any clinical, experimental or translational aspects of Nervous System Diseases for consideration by the Committee for Poster Presentation through Online Abstract Submission.

Authors are required to submit abstracts through Online Abstract Submission. Facsimile or email copy will NOT be accepted.

Submission Procedure
  1. Please register for the Conference (HERE) to receive the Registration ID; Or
  2. If you have already registered, use your registered email address & received Registration ID for online abstract submission (HERE).
  3. Abstracts shall be submitted on or before 21 January 2022 Hong Kong Time.
  4. For guidelines and sample template of the abstract, please click HERE.

Arrangement for Poster Presentation
  1. Abstract author is required to prepare an electronic poster (E-poster) for the abstract accepted by BRAIN 2022. All posters will be displayed on BRAIN 2022 Website throughout the Conference period and within one year after the Conference.
  2. Poster display and presentation arrangement will be announced in due course.

Poster Presentation Award
  1. The top abstracts will be selected for oral presentation during the Conference. Certificates will be issued to all selected oral presentation posters.
  2. Winners for the Best Presentation Award will be awarded cash prizes*. Posters are judged by members of the organizing committee and chairpersons and consideration is given to scientific rigour, contribution to the field, relevance to the themes and overall presentation.

  3. *Three awards will be given with HK$1,000 each.

BRAIN 2022 Best Poster Presentation Award

Ms Maggie L.M. LAM, The Chinese University of Hong Kong, Hong Kong
Stronger Association was shown between Cognition with Pulsatility Index than with Conventional Imaging Markers in Community Elderly without Dementia

Ms Vera CAI, The Chinese University of Hong Kong, Hong Kong
Biomarkers for the Detection of Progressive Early Alzheimer's Disease

Prof Rong JIN, Penn State College of Medicine, USA
Preliminary Evaluation of the Therapeutic Potential of MIR-30C MIMIC Treatment in Acute Ischemic Stroke: Dose-Response and Therapeutic Time Window

SPONSORSHIP & EXHIBITION

Hybrid Exhibition will be held jointly with the Conference. This Conference provides a platform for sharing views and experience from world's leading experts in the fields of Neurosciences. It is indeed a perfect opportunity for the stakeholders in the industry to enhance corporate visibility in the fields and update with today's development. For further details on Sponsorship and Exhibition Opportunities, please contact the Conference Secretariat at brainconference@cuhk.edu.hk.

Virtual Exhibition
(in alphabetical order)

The Organising Committee wishes to thank all the following companies for their generous supports.
Abbott Medical (Hong Kong) LtdX
Suite 1608, Exchange Tower
33 Wang Chiu Road
Kowloon Bay, Hong Kong
(+852) 2996 7688
(+852) 2956 0622
www.hk.abbott
Abbott Medical (Hong Kong) Ltd
Baxter Healthcare LtdX
Suite 2701-03
Oxford House, Taikoo Place
Quarry Bay, Hong Kong
(+852) 2807 8500
(+852) 2807 8596
www.baxter.com
Baxter Healthcare Ltd
Boehringer Ingelheim (Hong Kong) LimitedX
Suites 1504-9, Great Eagle Centre
23 Harbour Road, Wanchai, Hong Kong
(+852) 2596 0033
(+852) 2827 0162
www.boehringer-ingelheim.com.hk
Boehringer Ingelheim (Hong Kong) Limited

BrainLab LimitedX
Unit 2502-2503, 25/F
Prosperity Centre, 25 Chong Yip Street
Kwun Tong, Kowloon, Hong Kong
(+852) 2413 4321
(+852) 2413 4321
www.brainlab.com
BrainLab Limited
Carl Zeiss Far East Co., Ltd.X
Unit 3012, Level 30, Tower 1
Metroplaza, 223 Hing Fong Road
Kwai Fong, N.T., Hong Kong
(+852) 2332 0402
(+852) 2780 0650
www.zeiss.com
Carl Zeiss Far East Co., Ltd.
Chindex Hong Kong LimitedX
Room 903, 9/F
No. 148 Electric Road
North Point, Hong Kong
(+852) 2547 1536
(+852) 2548 4664
www.chindexmedical.com
Chindex Hong Kong Limited

DCH Auriga (HK) LimitedX
11/F., Wyler Centre I
202-210 Tai Lin Pai Road
Kwai Chung, NT, Hong Kong
(+852) 3619 2823
www.dchauriga.com
DCH Auriga (HK) Limited
Elekta LimitedX
12/F, Railway Plaza
39 Chatham Road South
Tsim Sha Tsui, Hong Kong
(+852) 2891 2208
(+852) 2155 9213
www.elekta.com
Elekta Limited
ElsevierX
11/F, Oxford House
Taikoo Place 979 King’s Road
Quarry Bay, Hong Kong
(+852) 2965 1323
(+852) 2976 0778
www.elsevier.com
Elsevier

Greyon Healthcare Co. Ltd.X
Room 14, 3/F, Block A
Wah Tat Industrial Centre
8-10 Wah Sing Street, Kwai Chung
N.T., Hong Kong
(+852) 2370 3168
Greyon Healthcare Co. Ltd.
Johnson & Johnson (Hong Kong) Ltd.X
13/F, Tower 1, Grand Century Place
193 Prince Edward Road West
MongKok, Kowloon, Hong Kong
(+852) 2738 6000
(+852) 2736 8697
www.depuysynthes.com
Johnson & Johnson (Hong Kong) Ltd.
KARL STORZ Endoscopy China LtdX
25th Floor, AXA Tower, Landmark East
100 How Ming Street, Kwun Tong
Kowloon, Hong Kong
(+852) 2865 2411
(+852) 2865 4114
www.karlstorz.com
KARL STORZ Endoscopy China Ltd

Medtronic Hong Kong Medical LimitedX
Suite 1104-1111, 11/F, Tower 1
The Gateway, Harbour City
Tsim Sha Tsui, Kowloon, Hong Kong
(+852) 2919 6550
(+852) 2891 6572
www.medtronic.com.hk
Medtronic Hong Kong Medical Limited
Novartis Pharmaceuticals (HK) LimitedX
7/F, Citi Tower, One Bay East
83 Hoi Bun Road, Kwun Tong
Kowloon, Hong Kong
(+852) 2881 4424
(+852) 2159 7242
www.novartis.com
Novartis Pharmaceuticals (HK) Limited
Nutricia Clinical (Hong Kong) LimitedX
33/F, Lee & Man Commercial Center
North Point, Hong Kong
(+852) 3460 5498
(+852) 2191 8162
www.souvenaid.com.hk
Nutricia Clinical (Hong Kong) Limited

Otsuka Pharmaceutical (H.K.) Ltd.X
21/F, East Exchange Tower
38 Leighton Road
Causeway Bay, Hong Kong
(+852) 2881 6299
(+852) 2577 5206
www.otsuka.hk/zh/cardio-page.php?yes=1
Otsuka Pharmaceutical (H.K.) Ltd.
Pfizer Corporation Hong Kong LimitedX
21/F, Kerry Centre, 683 King’s Road
Quarry Bay, Hong Kong
(+852) 5208 2357
(+852) 2579 0599
www.pfizer.com.hk
Pfizer Corporation Hong Kong Limited
Prism Technologies LimitedX
Unit 604, Yee Kuk Industrial Centre
555 Yee Kuk Street
Cheung Sha Wan, Hong Kong
(+852) 2786 3233
(+852) 2786 3812
www.prismtech.com.hk
Prism Technologies Limited

Synapse Therapeutics LimitedX
Unit 902, 9/F
Exchange Tower
33 Wang Chiu Road, Kowloon Bay
Kowloon, Hong Kong
(+852) 3188 1638
(+852) 3188 4466
Synapse Therapeutics Limited
Teva Pharmaceutical Hong Kong LimitedX
Unit 2303, 23/F., Mira Place Tower A
132 Nathan Road, Tsim Sha Tsui
(+852) 3701 9177
www.tevapharm.hk/en/hong-kong
Teva Pharmaceutical Hong Kong Limited
Zai Lab (Hong Kong) LimitedX
Room 2301, Island Place Tower
510 King’s Road
North Point, Hong Kong
(+852) 3844 8114
(+852) 3844 8188
www.zailaboratory.com
Zai Lab (Hong Kong) Limited

X

The Neural Basis of Sound Processing - Implications for the Perception of Speech
Sophie SCOTT

X

Probing Synaptic and Plasticity Deficits in Neurodevelopmental Disorders
Jacque Pak Kan IP

X

Mobile Exoneuromusculoskeleton for Telerehabilitation after Stroke
Xiaoling HU

Stroke is a leading cause of long-term disability in adults. However, regular and intensive physical training is hard to be accessed by discharged patients because of limited outpatient resources and interruptions by pandemics, e.g., COVID-19. Effective and self-help telerehabilitation with remote professional supervision is needed for long-term post-stroke rehabilitation. A hybrid robotic arm was invented for post-stroke upper limb rehabilitation at different joints, i.e., the elbow, wrist and fingers. It integrated the advantages of neuromuscular electrical stimulation, soft artificial muscle and exoskeleton in one system (exoneuromusculoskeleton), with the purposes to improve the robot-assisted rehabilitative effectiveness after stroke and to provide a novel rehabilitation service, i.e., self-help and mobile telerehabilitation for outpatients. The invention received a series of international awards and has been recognized as one of the five key developments which will impact the rehabilitation robotic global market in the near future. The technology and the service model are undergoing the process of commercialization, in collaboration with local companies and hospitals mainly located in the Greater Bay Area of China.

X

Cerebral Hemodynamics in Intracranial Atherosclerotic Disease
Cindy LENG

Background and objectives: Intracranial atherosclerotic disease (ICAD) is an important cause of ischemic stroke, particularly in East Asian populations. Those with an ischemic stroke attributed to ICAD (i.e., symptomatic ICAD) face a considerable risk of stroke relapse despite guideline-recommended, best medical treatment. We aimed to investigate the clinical relevance of cerebral hemodynamics in symptomatic ICAD.

Methods: In a series of studies, we used a computational fluid dynamics (CFD) model constructed based on CT angiography images to simulate blood flow across a symptomatic ICAD lesion. Translesional pressure ratio (PR) and translesional wall shear stress ratio (WSSR) were obtained in the CFD model to quantify the relative changes of these two hemodynamic metrics across a symptomatic ICAD lesion, when a low PR (relatively large pressure gradient across the lesion) and high WSSR (significantly elevated wall shear stress upon the lesion) indicate a hemodynamically more severe ICAD lesion.

Results: We found that symptomatic ICAD patients with a low PR and a high WSSR had a significantly higher risk of recurrent ischemic stroke in the same territory than those with normal PR and WSSR, despite best medical treatment, with hypoperfusion and/or artery-to-artery embolism as the probable mechanisms of most of the recurrent strokes. We have also identified a significant association between wall shear stress measures across symptomatic ICAD lesion and evolution of luminal stenosis in the lesion in medically treated patients. Moreover, we have also associated low PR and high WSSR with more severe covert cerebral small vessel disease burden in the ipsilateral hemisphere, in those with symptomatic ICAD in the anterior circulation.

Conclusions: Cerebral hemodynamics plays an important role in governing lesion evolution and the mechanisms and risk of stroke in ICAD, which may also underlie the development/progression of cerebral small vessel disease.

X

Direct Oral Anticoagulants - Insights from International and Local Real World Data
Bonaventure IP

X

Hong Kong Lower-grade Glioma Registry
Peter Y.M. WOO

X

Molecular Pathology of IDH Mutant Gliomas: The Unanswered Questions
Ho-Keung NG

X

Prediction of Molecular Pathology in Glioma from MRI Using AI
Zhenyu ZHANG

Stroke is a leading cause of long-term disability in adults. However, regular and intensive physical training is hard to be accessed by discharged patients because of limited outpatient resources and interruptions by pandemics, e.g., COVID-19. Effective and self-help telerehabilitation with remote professional supervision is needed for long-term post-stroke rehabilitation. A hybrid robotic arm was invented for post-stroke upper limb rehabilitation at different joints, i.e., the elbow, wrist and fingers. It integrated the advantages of neuromuscular electrical stimulation, soft artificial muscle and exoskeleton in one system (exoneuromusculoskeleton), with the purposes to improve the robot-assisted rehabilitative effectiveness after stroke and to provide a novel rehabilitation service, i.e., self-help and mobile telerehabilitation for outpatients. The invention received a series of international awards and has been recognized as one of the five key developments which will impact the rehabilitation robotic global market in the near future. The technology and the service model are undergoing the process of commercialization, in collaboration with local companies and hospitals mainly located in the Greater Bay Area of China.

X

Translational Therapy of Gliomas - Looking Beyond Conventional Targets
Vinay K. PUDUVALLI

X

Trials of CODEL & CATNON and the Up-to-date Standard of Care Treatment
Martin J van den BENT

X

REM Sleep Behavioral Disorder and a- Synucelinopathy - A Window to Prevent Neurodegeneration
Yun Kwok WING

Rapid eye movement (REM) sleep behavior disorder (RBD) is a distinct parasomnia characterized by repetitive occurrence of dream enactment behaviors related to vivid dreams and the loss of REM sleep related atonia (preservation of electromyography activity during REM sleep). Since the first discovery of RBD by Schenck and his colleagues in 1986, accumulating evidence has suggested that RBD is a prodromal stage of alpha-synucleinopathy, as over 90% of patients with idiopathic RBD would eventually develop alpha-synucleinopathies including Parkinson’s disease, dementia with Lewy body, and multiple system atrophy within 15 years of RBD diagnosis. By exploring the clinical profiles, developing assessment tools and diagnostic criteria, investigating the pathological mechanisms, determining the conversion rate to alpha-synucleinopathy, and identifying the neurodegenerative biomarkers in RBD, the ultimate aim is to delineate the progression of neurodegeneration and to develop neuroprotective therapy in preventing the neurodegeneration. In this talk, Prof. Wing will summarize the findings of previous studies on RBD and neurodegeneration and discuss future research directions and related challenges especially related to early diagnosis, high risk relatives, gut-brain hypothesis and psychiatric comorbidties and differential/converging motor and cognition pathways in the synucleinopathy outcome.

X

Gastrointestinal Dysfunction and Microbiota in Parkinson's Disease
Filip SCHEPERJANS

Gastrointestinal dysfunction affects up to 80% of Parkinson’s disease (PD) patients and may precede the onset of motor symptoms by years. It can heavily impact quality of life and pharmacological treatment. Neurodegenerative changes in the enteric nervous system can be found in earliest stages of PD. The colonic mucosa of PD patients shows an impaired barrier function, inflammation, oxidative stress, and bacterial invasion. There is accumulating evidence for an intense bidirectional interaction between gut microbiota and the brain influencing neuronal activity, behavior, as well as levels of neurotransmitter receptors, neurotrophic factors, and neuroinflammation. Pathways involving gut inflammation, amyloid cross-seeding, and short chain fatty acids may directly link gut microbiota and neurodegeneration.
Alterations of gut microbiome composition in PD have been shown in multiple studies suggesting that gut microbiota are related to PD, motor and non-motor symptoms, and disease progression. Recent research has revealed how gut microbiota interact with the host in PD through metabolic, immunologic, and epigenetic mechanisms. Gut microbiota changes have also been found in the prodromal phase of PD, namely subjects with isolated REM sleep behavior disorder (iRBD), and have been linked to several risk and prodromal markers of PD. Furthermore, increased exposure to antibiotics may increase PD risk and gut bacteria may impact drug absorption in PD. Thus, the gut and microbiota emerge as a crucial determinant of PD phenotype across different disease stages and may thus provide new diagnostic and therapeutic targets for a more individualized and disease-modifying treatment of PD.

X

Olfactory Function in Parkinson's Disease
Thomas HUMMEL

There is evidence from numerous studies, using both psychophysical and electrophysiological approaches, that impairment of olfaction is a characteristic and early feature of Parkinson´s disease. Deficits in the sense of smell precede clinical motor symptoms by years and can be used to assess risk for developing Parkinson´s disease in otherwise asymptomatic individuals. Recent data indicate that >95% of patients with Parkinson´s disease present with significant olfactory loss. Olfactory dysfunction is a reliable marker of the disease which is helpful in early and differential diagnosis.

X

A Tale of Two Frames - from Leksell G to Leksell Vantage
Danny T.M. CHAN

X

Directional Deep Brain Stimulation under General Anesthesia
Shin-Yuan CHEN

Background: Stereotactic implantation of electrode into deep seated nucleus may be resulted with substantial error and causing side-effects. Segmented directional deep brain stimulation (D-DBS) device may widen the therapeutic threshold. Because of fear and advanced symptoms of the patient, we have performed DBS under anesthesia for decades. Here we report our preliminary outcome on D-DBS.
Methods: From 2019/03 ~ 2021/06, a total of 51 cases (50 Parkinson’s disease, PD and 1 tardive dystonia) were underwent directional deep brain stimulation (D-DBS) at Hualien Tzu Chi General Hospital. Surgery was performed under inhalation general anesthesia and assisted with intraoperative microelectrode recording. Post-op image fusion and acute stimulation test were performed. The least possible direction was choosing for chronic stimulation.
Result: Twenty-eight PD patients (n=56 implants) were followed by a mean of 8.4±4.1months (3~17months). UPDRS part 3 was improved by a mean of 33±13%, LEDD was reduced by 51±27%. One patient committed self-mutilation during hospitalization with one-segment (direction) stimulation and was resulted with intracranial hemorrhage, whom recovered well with conservative treatment. Otherwise, no revision nor infection. Initial setting with one segment stimulation was 82%(n=46), two segments 11%(n=6), and all segments (omnidirectional) 7%(n=4). At the time of follow-up, the incidence of one segment stimulation was reduced from 82% to 27%, two segments stimulation was increased from 11% to 23% and omnidirectional was increased from 7% to 50%. The mean stimulation amplitude(mA) and impedance were: one segment stimulation 1.95±0.33/1992±428; two segments stimulation 2.46±0.59/1428±124; omnidirectional 2.06±0.70/1185±199.
Conclusion: DBS under general anesthesia is feasible and the treatment outcome was not inferior to the traditional awake surgery. The advent of directional stimulation may widen the therapeutic window. However, omnidirectional stimulation is suggested to be the initial setting for chronic stimulation, if acute stimulation test up to 4mA has no side effects. Raising the amplitude slowly in one segment (direction) stimulation, to avoid possible over stimulation side effects.

X

Application of Intraoperative CT in Robot-Assisted Deep Brain Stimulation
Xiaodong CAI

To introduce the application of intraoperative computed tomography (iCT) in Robot-Assisted Deep Brain Stimulation surgery and discuss the advantage and disadvantage of iCT based on our center’s experience.

X

Interventional MRI (iMRI) - guided Deep Brain Stimulation (DBS)
Paul S. LARSON

In the past, the gold standard for implantation of deep brain stimulator (DBS) electrodes was awake surgery with some form of physiologic mapping to confirm proper electrode placement. Techniques for physiologic mapping include single or multi-unit microelectrode recording, local field potential recording, micro- or macro-stimulation with observation of physiologic response or a combination of these techniques. At many centers in the United States and elsewhere, surgeons have moved to purely image-guided placement under general anesthesia. This so called “asleep DBS” technique was initially developed using interventional MRI (iMRI), but other groups have adopted interventional CT (iCT) as an alternative to MRI-guided surgery. An overview of the iMRI DBS procedure and its rationale will be provided, as well as a discussion of the pros and cons of awake versus asleep surgery, iMRI vs iCT and the clinical outcomes with iMRI-guided surgery as compared to traditional awake surgery. We will also explore future applications of iMRI for brain disorders beyond DBS.

X

Movement disorders and Their Stereotactic Surgical Treatment: A Retrospective Study of 5126 Patients at a Single Clinical Center over 22 Years
Yongjie LI

X

A Biological Definition of Alzheimer's Disease: NIA-AA Research Framework Present and Future
Clifford R. JACK

X

Machine Learning Derived Biomarker Based on MRI for Alzheimer's Disease
Vincent MOK

Structural magnetic resonance imaging (MRI) is currently the preferred first-line brain imaging modality for the evaluation of cognitive impairment. MRI is very useful in detecting cerebrovascular disease (e.g., silent infarcts) or in ruling out rare brain diseases (e.g., normal pressure hydrocephalus) that may account for the cognitive impairment. It can also serve as an imaging biomarker for Alzheimer’s disease (AD) as the pattern and severity of neurodegeneration (e.g., medial temporal lobe atrophy [MTA]) associated with AD can also be captured by MRI. Simple visual scale (e.g., Scheltens scale, score of 0 to 4) has been used to grade the severity of MTA over the past few decades. Although it can be easily applied in real-life clinical setting and has good diagnostic accuracy in diagnosing Alzheimer's dementia, it has only fair accuracy for diagnosing prodromal AD and low inter- and intra-rater reliability among inexperienced raters. In recent years, with further advancement in MRI post-processing technology, fully automated and accurate quantification of regional brain volumes (e.g., hippocampus) becomes feasible. Moreover, some post-processing pipelines were further translated into clinical applicable software that can be integrated into the management workflow of real-life clinical setting. These pipelines commonly include easy uploading of the imaging data to designated cloud platforms where data will be analysed, and automated generation of volumetric results back to the end users (e.g., radiologist) quickly. Although test-retest reliability of current software is usually excellent, different software may yield variable inter-scans reliability. Studies have consistently shown that volumetric measure outperform visual assessment in the diagnosis of prodromal AD or in the prognostication of mild cognitive impairment (MCI). In addition, given small change in hippocampal volume can be quantified over time, volumetry may be used to monitor disease progression or as surrogate outcome in clinical trials.

Apart from MTA, atrophy affecting other brain regions (e.g., entire temporal lobe, parietal and frontal lobe) is also present even at the preclinical stage and increases further as the disease continues to progress. With the advent of machine learning technology, difference in the various features detectable by structural MRI (e.g., regional volumes, tissue density, morphological feature of the cortical surface) between the “diseased” and “normal” brains can be recognised and be transformed into algorithms that can aid disease classification. Many studies published over the past two decades demonstrated the feasibility of applying machine learning technology upon MR scans for the differentiation between “AD dementia” and “normal” or between “progressive MCI” and “stable MCI”. Few studies had further derived a continuous “index” or “score” (e.g., from 0 to 100%) that reflects the similarity of the individual brain’s atrophy pattern to that of subjects with Alzheimer’s dementia. Many studies showed that machine learning-derived MRI-based biomarker based on multi-structure volumetric measures outperformed that of single volumetric measure in the diagnosis of AD or prognostication of MCI. In this lecture, we will report one of world first software that is able to generate not only multi-structure brain volumetry, but also a machine-learning derived integrated “index” that has been applied and validated in real-life clinical setting for the management of patients presenting with cognitive impairment.

X

Retinal Biomarkers for Alzheimer's Disease
Carol CHEUNG

Identifying biomarkers of Alzheimer's disease (AD) will accelerate the understanding of its pathophysiology, facilitate screening and risk stratification, and aid in developing new therapies. Developments in non-invasive retinal imaging technologies, including optical coherence tomography (OCT), OCT angiography and digital retinal photography, have provided a means to study neuronal and vascular structures in the retina in people with AD. Both qualitative and quantitative measurements from these retinal imaging technologies have been shown to be associated with cognitive function impairment and risk of AD. The development of computer algorithms for respective retinal imaging methods has further enhanced the potential of retinal imaging as a viable tool for rapid, early detection and screening of AD. In this talk, I present an update of current retinal imaging techniques and their potential applications in AD research. The directions in this expanding field will also be discussed.

X

Chemical Exchange Saturation Transfer (CEST) MRI for Alzheimer's Disease
Kannie CHAN

Gastrointestinal dysfunction affects up to 80% of Parkinson’s disease (PD) patients and may precede the onset of motor symptoms by years. It can heavily impact quality of life and pharmacological treatment. Neurodegenerative changes in the enteric nervous system can be found in earliest stages of PD. The colonic mucosa of PD patients shows an impaired barrier function, inflammation, oxidative stress, and bacterial invasion. There is accumulating evidence for an intense bidirectional interaction between gut microbiota and the brain influencing neuronal activity, behavior, as well as levels of neurotransmitter receptors, neurotrophic factors, and neuroinflammation. Pathways involving gut inflammation, amyloid cross-seeding, and short chain fatty acids may directly link gut microbiota and neurodegeneration.
Alterations of gut microbiome composition in PD have been shown in multiple studies suggesting that gut microbiota are related to PD, motor and non-motor symptoms, and disease progression. Recent research has revealed how gut microbiota interact with the host in PD through metabolic, immunologic, and epigenetic mechanisms. Gut microbiota changes have also been found in the prodromal phase of PD, namely subjects with isolated REM sleep behavior disorder (iRBD), and have been linked to several risk and prodromal markers of PD. Furthermore, increased exposure to antibiotics may increase PD risk and gut bacteria may impact drug absorption in PD. Thus, the gut and microbiota emerge as a crucial determinant of PD phenotype across different disease stages and may thus provide new diagnostic and therapeutic targets for a more individualized and disease-modifying treatment of PD.

X

scONE-seq: A One-tube Single-cell Multi-omics Method Enables Simultaneous Dissection of Molecular Phenotype and Genotype Heterogeneity from Frozen Tumors
Angela R. WU

Genomic and transcriptomic heterogeneity both play important roles in normal cellular function as well as in disease development. To be able to characterize these different forms of cellular heterogeneity in diverse sample types, we developed scONE-seq, which enables simultaneous transcriptome and genome profiling in a one-tube reaction. Previous single-cell-whole-genome-RNA-sequencing (scWGS-RNA-seq) methods require physical separation of DNA and RNA, often by physical separation of the nucleus from the cytoplasm. These methods are labor-intensive and technically demanding, time-consuming, or require special devices, and they are not applicable to frozen samples that cannot generate intact single-cell suspensions. scONE-seq is a one-tube reaction, thus is highly scalable and is the first scWGS-RNA-seq method compatible with frozen biobanked tissue. We benchmarked scONE-seq against existing methods using cell lines and lymphocytes from a healthy donor, and we applied it to a 2-year-frozen astrocytoma sample profiling over 1,200 nuclei, subsequently identifying a unique transcriptionally normal-like tumor clone. scONE-seq makes it possible to perform large-scale single-cell multi-omics interrogation with ease on the vast quantities of biobanked tissue, which could transform the scale of future multi-omics single-cell cancer profiling studies.

X

Identification of Early Predictors of Glioblastoma Evolution under Therapy
Jiguang WANG

Clonal evolution of cancer is a major challenge leading to treatment failure, but the molecular mechanisms of how cancer cells evolve and gain the capability of surviving intensive chemo- and/or radio- therapies remain elusive. Therefore, it is critically important to characterize the spatial and temporal dynamics of cancer cells and thereby mathematically modelling this process via big data integration. We have been working on diffuse gliomas, the most common and aggressive forms of primary tumors in adult brain whose treatment outcome is still very poor. Current therapies inevitably lead to tumor recurrence and the recurrent gliomas commonly become treatment resistance and incurable. Analyzing longitudinal and single-cell multi-omics data on this disease, our team aims to address the following questions: a) why cancer cells always display complex patterns of intratumoral heterogeneity; b) what is the temporal order of multiple somatic mutations detected in various cancer clones; c) how to predict the evolutionary path and clinical response of cancer cells under a certain therapy based on the sign seen earlier; and d) what are the key factors in tumor and its microenvironment that shape cancer evolution and determine cancer cell response under clinical intervention. In the process of addressing these questions, we will be able to unravel the mysteries of cancer evolution and it might provide a theoretical foundation for designing new means of treatment or diagnostics for better precision cancer medicine via targeting cancer dynamics.

X

The Epigenetic Mechanism and Clinical Translation of Metabolic Profiling in IDH Mutated Gliomas
Harvey W. HUA

IDH mutation was first found in gliomas by Duke group in 2008, and over 80% lower grade gliomas (grade II and III) harbored IDH mutation. IDH mutation could specifically induce 2-HG accumulation, which functionally altered the epigenetics in gliomas. IDH mutated gliomas are quite unique in clinical, as they favor young patients and frontal lobe. IDH mutated gliomas also could benefit from chemotherapy and total neurosurgical resection. So, it is important to extend the application of this special metabolic change in clinic management.
Previously, we found proline could be synchronously upregulated with 2-HG accumulation (Cell reports, 2018). We also investigated the metabolic profiling between IDH mutated and wild type gliomas. This metabolic reshape could be applied in PET-CT (BMC Cancer, 2021) and MRS for IDH mutation identification. In the meantime, metabolic profiling could also be rapidly detected intraoperatively with mass spectrometer (Lab Inv, 2018). We could identify 2-HG accumulation in 3 minutes with Mini-beta mass spectrometer intraoperatively, which was trained with 115 patients and validated with 75 patients. Meanwhile, real time metabolic photograph and delineation could be obtained in theatre.

X

Non-mitotic Mode of Proliferation in Primary Cancer Cells and Cell Lines
Hannah H. XUE

Meningeal hemangiopericytomas (HPC) are rare tumors of the meninges, aggressive versions of solitary fibrous tumors of the dura with high risk of reoccurrence. To understand the factors underlying the relapse of these rare tumors, comparative analysis at the genomic and cellular levels was performed based on AluScan sequencing on a recurrent chemotherapy-treated (Case 1) and benign (Case 2) cases. In genomic level, both cases showed CG to TG mutations along with TG to CG ones, particularly in the second-recurrence tissue of Case 1 (C1T3). At the cellular level, high frequency of multinucleation was observed in C1T3, along with increased non-mitotic modes of proliferation including cannibalism, shedding and tunneling when mitosis was suppressed. Furthermore, cell lines under cisplatin or epirubicin treatment showed variable cellular responses that included both mitotic and non-mitotic events. These findings suggest that when mitosis was reduced, aberrant proliferative prokaryotic characteristics become manifest which could contribute to cancer relapse. Therefore, an improved understanding of deviations from standard mitotic proliferation may represent an important aspect of cancer cell behavior that requires further investigation.

X

Stronger Association was shown between Cognition with Pulsatility Index than with Conventional Imaging Markers in Community Elderly without Dementia
Maggie L.M. LAM

X

Application of Pre-Hospital Identification and Notification of Stroke Patients (Pre-act) Initiative to the Management of Haemorrhagic Stroke
Queenie H.W. WONG

X

Dynamic Changes in Automatic Generated Quantitative Biomarkers - A Longitudinal Study
Xiang FAN

X

Biomarkers for the Detection of Progressive Early Alzheimer's Disease
Vera CAI

X

Glioblastoma Patient Survival Predictors treated by the Hong Kong Hospital Authority: A Multicenter Retrospective 15-year Review
Chi Chun LAM

X

Integrative Medicine as an Alternative Approach to Reduce Fatigue and Inflammation in Multiple Sclerosis
Angel NG

X

A Novel Brain Biopsy Cannula for Safe and Adequate Tissue Acquisition
Yitian XIAN

X

Mapping Structural Disconnection to Behavioral Dysexecutive Symptoms in Subcortical Stroke
Lisha WANG

X

The Development of DBS Device in China and Future Direction
Luming LI

X

Clinical Application of Directional Lead and Virtual Clinic to DBS Patients
Binith J. CHEERAN

The past decade has seen rapid progress in Deep Brain Stimulation Technology. This lecture will focus on one hardware (Directional Leads) and one software advance (Remote Programming), from ideation to implementation and clinical evidence development. The lecture will also offer the speakers personal views on future developments in the space.
Learning Goals:
1.Directional Lead design, biophysics and clinical evidence review
2.Remote Programming necessity, utility and clinical evidence review
Future developments: Remote monitoring, Sensing, Analytics

X

Personalised DBS Programming: Delivering Patient Specific Stimulation by Combining High-resolution Stimulation Control with Image Guided Programming Capabilities
Peter J. YOO

X

Workflow Considerations for BrainSense Technology
Sol T. De JESUS

X

The Spatial and Temporal Dynamics of Microglia Cells Following Transient Focal Cerebral Ischemia
Cyrus W. C. CHENG

X

Pax6/C-MYB Mediates Neuroinflammation and Amyloid Beta Clearance in a Term2 Dependent Manner in Alzheimer's Disease
Yi ZHANG

X

Preliminary Evaluation of the Therapeutic Potential of MIR-30C MIMIC Treatment in Acute Ischemic Stroke: Dose-Response and Therapeutic Time Window
Rong JIN

X

Current Management of Atypical Glioma
Martin J van den BENT

CONFERENCE INFORMATION

Date
25-26 February 2022 (Friday - Saturday)

Time Zone
All communicated times in the Scientific Programme are Hong Kong Time. Hong Kong is 8 hours ahead of Greenwich Mean Time (i.e. GMT + 8 hours).

Format
Online Webinar

Official Language
The official language of the Conference is English. There will be no translation provided.

Registration
All registrations should be made through the Online Registration.

Webcast
Conference will be webcasted via this website. It is highly recommended to join the webinar from the computer for the best experience. The webinar is NOT supported on the mobile version of web browsers.

Trade Exhibition
A virtual exhibition of medical equipment, books and pharmaceutical brochures will be held during the Conference on 25 - 26 February 2022.

Letter of Invitation
The Organising Committee would be pleased to provide letters of invitation (without provisions of financial support) upon request. Please address your request to the Conference Secretariat.

Academic Accreditations (for local participants)
Continuing Medical Education (CME), Continuing Nursing Education (CNE) and Continuing Professional Development (CPD) accreditation will be applied from relevant Hong Kong colleges and associations. Accreditation will be given on condition that the College fellows/ Association members are required to sign in and attend the Virtual Conference on 25 - 26 February 2022 to document the attendance.

CME/CNE/CPD points will be given based on the corresponding login/logout time of the live webinar unless otherwise stated. For the approved points awarded by Hong Kong colleges and associations, please click HERE.

Certificate of Attendance
E-Certificate of Attendance will be issued after the Conference via email.

Liability and Insurance
The Organiser is not responsible for injury or damage involving persons and property during the Conference. Participants are advised to make their own arrangements for their medical, travel and personal insurance. Equipment and all related display materials installed by Exhibitors / Sponsors are not insured by the Organiser, and the Organiser under no circumstances will be liable for any loss, damage or destruction caused to equipment, goods or property belonging to Exhibitors/Sponsors.

Disclaimer
Whilst every attempt is made to ensure that all aspects of the Conference as mentioned in this website will take place as scheduled, the Organising Committee reserves the right to make changes should the need arise.

CONTACT US

Division of Neurology
Department of Medicine and Therapeutics
The Chinese University of Hong Kong

9/F Lui Che Woo Clinical Sciences Building
Prince of Wales Hospital, Shatin, Hong Kong

Tel: (852) 2895 3968/ 2674 7866

Fax: (852) 2295 4399

E-mail: brainconference@cuhk.edu.hk

Website: cu-brain.cuhk.edu.hk

Abstract Submission ( Required Fields )X

The email address should be the same as the email used to register the conference.

Your Registered Email
ABSTRACT DETAILS
Title
Authors
Institution
Country
Abstract
(Must not exceed 300 words)

Guidelines for Submission of Abstracts

Sample Abstract

Online Registration ( Required Fields ) X

In response to the rapidly changing COIVI-19 outbreak in Hong Kong, the BRAIN 2022 Conference will be held FULLY VIRTUAL.

Title
Surname
Given Name
Position
Department
Institution
Mailing Address
Region
Profession
Tel
Fax
Email
Confirm Email

Academic Accreditation (CME, CNE, and CPD credits are available for local participants)
Please provide adequate information for the acquisition of CME/ CNE/ CPD points.

College/ Association
MCHK Reg No. (Non-specialists)
e-learning ID